Disclaimer: Note that the firm is no longer accepting cases for the anti-psychotic medication Abilify, Tylenol autism cases, Jardiance cases connected to Fournier gangrene, or any other anti-psychotic medication cases. Thank you.
Select Page

Oxbryta Recall: What You Need to Know

2 minute read

What is Oxbryta?

Oxbryta is a prescription medication developed to help people with sickle cell disease (SCD). It works by improving the oxygen-carrying ability of red blood cells and reducing the complications that come with SCD, like pain crises and organ damage. While it’s been seen as a breakthrough for managing this condition, a recent recall has raised serious concerns about its safety. [1]

What Happened with the Recall?

On December 12, 2024, Global Blood Therapeutics issued a recall for specific batches of Oxbryta after discovering contamination with foreign particles in some of the tablets. The recall affects multiple lots that were distributed across the U.S. [2] 

This is classified as a Class I recall the FDA’s most serious category, meaning the product could cause severe injuries or even death. Patients and healthcare providers have been told to stop using the affected batches immediately. [3] 

What Injuries Can Oxbryta Cause?

The contaminated tablets have been linked to several injuries, including:

  • Stomach issues, like nausea, pain, or inflammation from the foreign
  • Breathing problems, especially if the particles are inhaled or travel through the
  • Organ damage or infections can be especially dangerous for people already dealing with health challenges caused by sickle cell disease.

SCD patients are already vulnerable to health complications, and this contamination only adds to the risks. [4]

How We Can Help

At the Michael Lynch Firm, we’re handling cases for people who’ve been harmed by Oxbryta. If you or someone you care about has been injured, let us fight for you. You may be entitled to compensation for your medical bills, pain, and other damages. Call us at 888-585-5970 or email brandon@mblynchfirm.com for a free consultation.

Date: December 17, 2024

Editor-in-Chief: Brandon Salter

Editor: Sonya Coenen

Citations

[1] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease

[2] https://www.reuters.com/business/healthcare-pharmaceuticals/fda-alerts-patients-about-pfizers-oxbryta-withdrawal-2024-09-26/

[3] https://www.ema.europa.eu/en/news/ema-recommends-suspension-sickle-cell-disease-medicine-oxbryta

[4] https://www.investopedia.com/pfizer-recalls-all-of-its-sickle-cell-disease-treatment-over-safety-concerns-8718725

Ormond Beach Abuse Investigation: Riverbend Academy

Ormond Beach Abuse Investigation: Riverbend Academy

Multidistrict litigation (MDL No. 3094) involving GLP-1 receptor agonist medications, such as Ozempic, Wegovy, and Mounjaro, is actively moving forward in the Eastern District of Pennsylvania. Plaintiffs allege that the manufacturers failed to warn users about serious health risks, including gastroparesis, intestinal blockages, and vision loss.

read more
Ozempic, Wegovy & Mounjouro MDL Lawsuit: Latest Updates

Ozempic, Wegovy & Mounjouro MDL Lawsuit: Latest Updates

Multidistrict litigation (MDL No. 3094) involving GLP-1 receptor agonist medications, such as Ozempic, Wegovy, and Mounjaro, is actively moving forward in the Eastern District of Pennsylvania. Plaintiffs allege that the manufacturers failed to warn users about serious health risks, including gastroparesis, intestinal blockages, and vision loss.

read more
PFAS Lawsuit 2025 Update: What You Should Know

PFAS Lawsuit 2025 Update: What You Should Know

The PFAS multidistrict litigation (MDL No. 2873) is moving forward in the District of South Carolina, where over 10,000 cases remain active against major manufacturers like 3M, DuPont, and BASF. While 3M reached a $10 billion settlement in 2023 to resolve water utility claims, no global settlement has been reached for individual personal injury lawsuits.

read more
Fosamax MDL Update 2025: Legal Developments and Case Status

Fosamax MDL Update 2025: Legal Developments and Case Status

Fosamax (alendronate), a widely used osteoporosis drug, remains the subject of multidistrict litigation (MDL) over allegations that it can cause serious bone injuries, including atypical femur fractures and osteonecrosis of the jaw (ONJ). Plaintiffs claim Merck failed to warn users adequately about these risks.

read more
Paragard MDL Updates: What You Should Know

Paragard MDL Updates: What You Should Know

The Paragard IUD remains the subject of a major nationwide lawsuit, with claims alleging the device breaks during removal, leading to serious injuries that the manufacturers, Teva Pharmaceuticals, allegedly failed to adequately warn consumers about. These cases have been centralized in Multidistrict Litigation (MDL) No. 2974, in the Northern District of Georgia.

read more
Understanding the Pre-Litigation Process: What to Do After a Car Accident

Understanding the Pre-Litigation Process: What to Do After a Car Accident

The time period immediately following a car accident is crucial not only for your health, but for protecting your legal rights. Prior to any lawsuits being filed, you enter the pre-litigation phase during which critical steps must be taken. Knowing what to do after an accident can make a major difference in the outcome of your personal injury claim and help preserve your right to compensation.

read more
The Car Accident Negotiation Phase

The Car Accident Negotiation Phase

The negotiation phase after a car accident is often the toughest part of resolving your claim. Insurance companies are skilled at minimizing payouts and may challenge the seriousness of your injuries, the necessity of your medical treatment, or the legitimacy of your lost wages. Getting through this process requires more than patience, it demands strong documentation and experienced legal representation.

read more
×
What Our Clients Are Saying